fbpx Skip to main content

Topical or nasal probiotics are not a good choice for treating allergic rhinitis.

Topical probiotics have been proposed as a therapeutic alternative for allergic rhinitis because they might influence the immune response towards a type-1 non-allergic profile.

This randomized placebo-controlled crossover trial, published in Clinical & Experimental Allergy, aimed to determine whether a topical/nasal probiotic assemblage (PA) delivery affects signs, symptoms, and quality of life in patients with allergic rhinitis in a nasal allergen challenge (NAC).

The topical/nasal treatment of a PA of Lactobacillus rhamnosus SP1, Lactobacillus paracasei 101/37, and Lactococcus lactis L1A or placebo was randomly assigned to 24 patients with seasonal allergic rhinitis for 3 weeks. A NAC series was added to the final week of each treatment period. The Mini-Rhinoconjunctivitis Quality of Life Questionnaire (Mini-RQLQ), the total nasal symptom score (TNSS), peak nasal inspiratory flow (PNIF), and fractional exhaled nitric oxide (FeNO) were the efficacy variables. Additionally, soluble analytes in nasal lavage fluids were observed to determine whether or not the PA had any pro-inflammatory effect in and of itself. Finally, MALDI-TOF analysis was used to determine if bacteria cultures obtained using swabs from the middle nasal meatus contained PA.

Taking the PA did not cause any nasal symptoms (cf. placebo). An innate immune response was seen during the PA run (compared to baseline); however, the levels of cytokines and mediators in the nasal lavage fluid did not vary from placebo except for IL-17 and IL-17A. Mini-RQLQ, TNSS, PNIF, and FeNO were unaffected by PA administration.
The study concluded that topical or nasal probiotics are not effective for treating AR. Moreover, PA elicited a limited innate immune response. However, topical/nasal treatment for 3 weeks with the PA composed of Lactobacillus rhamnosus SP1, Lactobacillus paracasei 101/37, and Lactococcus lactis L1A did not affect AR symptoms when compared to placebo.

You May Also Like::  Regional Disparities in Asthma Education and Prevalence

Reference:
Mårtensson, A., Nordström, F. U., Cervin-Hoberg, C., Lindstedt, M., Sakellariou, C., Cervin, A., & Greiff, L. (2022). Nasal administration of a probiotic assemblage in allergic rhinitis: A randomised placebo-controlled crossover trial. Clinical and Experimental Allergy, 52(6), 774-783. doi:10.1111/cea.14098

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.

#dermtwitter
@AADmember

New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More